Clal Biotechnology Industries

Sight Diagnostics Ltd. is a medical device company based in Tel Aviv, Israel, that focuses on developing advanced diagnostic solutions for blood diseases. Utilizing proprietary machine-vision technology, the company has created a platform that leverages artificial intelligence for blood analysis and infectious disease detection. Its flagship product, Parasight, is a malaria detection device that accurately identifies and enumerates malaria through a digital fluorescent microscopy process. Since its launch in 2014, Sight Diagnostics has sold over 600,000 tests across 25 countries. Additionally, the company has introduced OLO, a device that facilitates complete blood count testing at the point-of-care, which is currently available in the European Union and other non-US markets. By providing scalable and precise blood diagnostics, Sight Diagnostics aims to enhance patient outcomes and improve overall healthcare accessibility.

Luc Therapeutics, founded in 2010 and based in Cambridge, Massachusetts, was a precision neuroscience company focused on developing novel allosteric modulators for ion channels aimed at improving neuronal firing regularity. The company specialized in creating subunit-selective NMDA receptor modulators, including NR2B negative allosteric modulators for depression and NR2B positive allosteric modulators to enhance cognitive function in schizophrenia. Additionally, it explored NR2A negative allosteric modulators to address disease progression and symptoms in Rett syndrome and other autism spectrum disorders. Luc Therapeutics was known for its innovative approach to restoring cognitive and motor functions in patients with serious neurological conditions by leveraging target specificity, patient selection, and drug optimization. In October 2017, Luc Therapeutics changed its name to Cadent Therapeutics.

Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer. It offers potent vaccines and immunotherapies that enables precise targeting and delivery of immunogens directly to the lymphatic system, substantially enhancing the body's own system of immune defenses.

Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/ß-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/ß-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/ß-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.

Colospan Ltd is a clinical-stage medical device company based in Kfar Saba, Israel, established in 2010. It specializes in developing innovative technology aimed at improving outcomes in colorectal surgeries. The company has created a proprietary, single-use intraluminal bypass device designed to minimize the risk of anastomotic leaks following intestinal surgery, particularly in patients with severe inflammatory bowel diseases or colorectal cancer. This device helps reduce contact between fecal matter and the anastomotic site, thereby decreasing the likelihood of complications that could lead to prolonged hospitalization or the need for additional surgeries. By offering a temporary alternative to diverting colostomies, Colospan's products aim to enhance patient recovery while maintaining overall well-being and safety during the post-operative period.

Gamida Cell Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, utilizes expanded hematopoietic stem cells and differentiated immune cells, and is currently undergoing Phase 3 trials for high-risk hematologic malignancies, alongside Phase 1/2 trials for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy, which is in Phase 1/2 studies for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company leverages a proprietary expansion platform that enhances the therapeutic potential of umbilical cord blood-derived cells and natural killer cells, aiming to address significant unmet clinical needs in the field of regenerative medicine.

Pi-Cardia is a medical device start-up focused on developing an innovative catheter designed to treat aortic stenosis. The company’s proprietary technology utilizes a low-profile trans-femoral catheter that incorporates nitinol elements to deliver mechanical impact, creating fractures in calcified heart valves without damaging the surrounding soft tissues. This procedure, which takes only a few seconds, aims to increase the effective orifice area of the valve, providing a less invasive alternative to valve replacement. Pi-Cardia's approach seeks to offer a cost-effective and durable treatment option for patients suffering from this condition.

Neon Therapeutics is a clinical-stage biopharmaceutical company specializing in neoantigen-targeted therapies aimed at advancing cancer treatment. By focusing on the immune system's response to neoantigens, the company seeks to develop innovative therapies that enhance the body's ability to fight cancer. Its product pipeline includes NEO-PV-01, NEO-PTC-01, and NEO-SV-01, which are designed to leverage the unique characteristics of neoantigens to improve patient outcomes.

Sight Diagnostics Ltd. is a medical device company based in Tel Aviv, Israel, that focuses on developing advanced diagnostic solutions for blood diseases. Utilizing proprietary machine-vision technology, the company has created a platform that leverages artificial intelligence for blood analysis and infectious disease detection. Its flagship product, Parasight, is a malaria detection device that accurately identifies and enumerates malaria through a digital fluorescent microscopy process. Since its launch in 2014, Sight Diagnostics has sold over 600,000 tests across 25 countries. Additionally, the company has introduced OLO, a device that facilitates complete blood count testing at the point-of-care, which is currently available in the European Union and other non-US markets. By providing scalable and precise blood diagnostics, Sight Diagnostics aims to enhance patient outcomes and improve overall healthcare accessibility.

CureTech Ltd. is a biotechnology company based in Yavne, Israel, established in 2001. It specializes in developing immune modulating products aimed at the treatment and control of cancer. The company focuses on creating antibodies and peptide therapeutics designed to enhance the immune response against various tumors. One of its key products is pidilizumab, a humanized monoclonal antibody known for its ability to provoke an effective anti-cancer immune response in both mouse and human tumors.

MediWound Ltd. is a biopharmaceutical company based in Yavne, Israel, that specializes in developing and commercializing innovative therapeutic products for severe burns, chronic wounds, and connective tissue disorders. The company's primary product, NexoBrid, is an FDA-approved biologic designed for the removal of eschar in patients with deep partial- and full-thickness thermal burns, offering a non-surgical alternative to traditional methods. MediWound also focuses on other product candidates, including EscharEx, which has completed Phase II clinical trials for the treatment of chronic wounds, and MWPC003, aimed at addressing connective tissue disorders. Founded in 2000, MediWound is committed to meeting unmet medical needs in wound management and improving patient outcomes through its advanced therapeutic solutions.

Luc Therapeutics, founded in 2010 and based in Cambridge, Massachusetts, was a precision neuroscience company focused on developing novel allosteric modulators for ion channels aimed at improving neuronal firing regularity. The company specialized in creating subunit-selective NMDA receptor modulators, including NR2B negative allosteric modulators for depression and NR2B positive allosteric modulators to enhance cognitive function in schizophrenia. Additionally, it explored NR2A negative allosteric modulators to address disease progression and symptoms in Rett syndrome and other autism spectrum disorders. Luc Therapeutics was known for its innovative approach to restoring cognitive and motor functions in patients with serious neurological conditions by leveraging target specificity, patient selection, and drug optimization. In October 2017, Luc Therapeutics changed its name to Cadent Therapeutics.

Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, established in 2010. The company focuses on developing innovative products aimed at the treatment and prevention of neurodegenerative disorders. Its lead product candidate, Ladostigil, is designed to address mild cognitive impairment and employs multifunctional compounds that offer neuroprotective benefits. These mechanisms include the reduction of oxidative stress and microglial activation, as well as the inhibition of pro-inflammatory cytokines. Avraham Pharmaceuticals has raised $9 million to support clinical trials, including a European Phase II proof-of-concept efficacy trial targeting Alzheimer's disease.

Gamida Cell Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, utilizes expanded hematopoietic stem cells and differentiated immune cells, and is currently undergoing Phase 3 trials for high-risk hematologic malignancies, alongside Phase 1/2 trials for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy, which is in Phase 1/2 studies for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company leverages a proprietary expansion platform that enhances the therapeutic potential of umbilical cord blood-derived cells and natural killer cells, aiming to address significant unmet clinical needs in the field of regenerative medicine.

Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, established in 2010. The company focuses on developing innovative products aimed at the treatment and prevention of neurodegenerative disorders. Its lead product candidate, Ladostigil, is designed to address mild cognitive impairment and employs multifunctional compounds that offer neuroprotective benefits. These mechanisms include the reduction of oxidative stress and microglial activation, as well as the inhibition of pro-inflammatory cytokines. Avraham Pharmaceuticals has raised $9 million to support clinical trials, including a European Phase II proof-of-concept efficacy trial targeting Alzheimer's disease.

Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, established in 2010. The company focuses on developing innovative products aimed at the treatment and prevention of neurodegenerative disorders. Its lead product candidate, Ladostigil, is designed to address mild cognitive impairment and employs multifunctional compounds that offer neuroprotective benefits. These mechanisms include the reduction of oxidative stress and microglial activation, as well as the inhibition of pro-inflammatory cytokines. Avraham Pharmaceuticals has raised $9 million to support clinical trials, including a European Phase II proof-of-concept efficacy trial targeting Alzheimer's disease.

ProtAb develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases. Its first product, Prozumab, is a monoclonal antibody with a novel mechanism of action. It is currently in late-stage preclinical development for the treatment of inflammatory bowel disease or IBD, ulcerative colitis or UC, and rheumatoid arthritis or RA. It operates as a subsidiary of Hadasit Bio-Holdings. HBL is a publicly traded subsidiary of Hadasit, the technology transfer company of the Hadassah University Hospital in Jerusalem in Israel.

Aposense Ltd. is a biopharmaceutical company focused on developing innovative drugs by leveraging the structural and electrical properties of biological membranes. The company specializes in creating molecular nano-motors, which are small chemical entities that harness energy from intra-membrane electric fields. Aposense's Apo-Si platform technology facilitates the delivery of genetic drugs, such as siRNA, into cells. The company's pipeline includes ATT-11T, a conjugate of its proprietary molecular nano-motor with SN-38, aimed at treating solid tumors. Additionally, Aposense is involved in clinical-stage molecular imaging and drug development, targeting apoptosis to enhance personalized patient care across various disease categories, including oncology, cardiology, and neurology. Founded in 1996 and headquartered in Petah Tikva, Israel, Aposense is dedicated to translating the science of apoptosis into effective therapies and real-time clinical imaging.

Polyheal Ltd. is an advanced medical device company based in Yavne, Israel, specializing in the development and commercialization of innovative wound care solutions. Founded in 1996, the company utilizes a proprietary technology involving negatively-charged microspheres to treat a variety of wounds, including chronic ulcers, burns, surgical and traumatic wounds. This sterile liquid suspension promotes active wound healing without the need for additional pharmacological agents. Polyheal's products are designed for various wound types, such as diabetic foot ulcers, pressure-induced ulcers, and those with exposed bone or foreign materials. In addition to its product offerings, the company provides training and education services to ensure effective use of its technology. Polyheal primarily serves patients in Europe and Israel.

D-Pharm (TASE: DPRM) is a drug-development company focused on innovative drugs for the treatment of central nervous system (CNS) conditions. The Company’s particular area of interest is in developing innovative medicine for degenerative and age-related disorders.

Compugen Ltd. is a clinical-stage therapeutic discovery and development company headquartered in Holon, Israel. The company focuses on immuno-oncology, leveraging its unique computational discovery capabilities to identify novel drug targets and biological pathways for cancer therapeutics. Compugen's immuno-oncology pipeline includes several clinical-stage programs, such as COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT, both designed for the treatment of solid tumors. Additionally, the company has early-stage programs addressing myeloid targets and various mechanisms of immune resistance. Compugen collaborates with notable partners, including Bayer Pharma AG and Bristol-Myers Squibb, to further research and develop its therapeutics. Founded in 1993, Compugen employs a hypothesis-driven approach to drug discovery, utilizing in silico methods for product candidate prediction and validation, enhancing its ability to meet unmet therapeutic needs in the pharmaceutical and biotech sectors.